Intermediate Expanded Access Protocol CNMAu8.EAP04
NCT06408727 · Status: TEMPORARILY_NOT_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-04-07
Summary
An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
Conditions
Interventions
- DRUG
-
CNM-Au8
CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
collaborator NIH -
Clene Nanomedicine
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy
NCT01093170 ·Status: WITHDRAWN ·Phase: PHASE1
-
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
NCT05286372 ·Status: APPROVED_FOR_MARKETING
-
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
NCT01753076 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
NCT05104476 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
NCT02628743 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
NCT02525471 ·Status: COMPLETED ·Phase: PHASE1
-
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)
NCT03843710 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
NCT05349721 ·Status: TERMINATED ·Phase: PHASE2
-
CuATSM Compared With Placebo for Treatment of ALS/MND
NCT04082832 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Enoxacin for Amyotrophic Lateral Sclerosis (ALS)
NCT04840823 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis
NCT06083584 ·Status: RECRUITING
-
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
NCT02870634 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States
NCT06747273 ·Status: TERMINATED ·Phase: PHASE1
-
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT01786603 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis
NCT04849065 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
NCT01492686 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of Tocilizumab in ALS Subjects
NCT02469896 ·Status: COMPLETED ·Phase: PHASE2
-
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
NCT06391645 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
ALS Reversals - Lunasin Regimen
NCT02709330 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Procedures to Support Research in ALS
NCT03489278 ·Status: RECRUITING
-
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis
NCT06318598 ·Status: RECRUITING
-
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05237284 ·Status: TERMINATED ·Phase: PHASE2
-
RT001 in Amyotrophic Lateral Sclerosis
NCT04762589 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT00330681 ·Status: COMPLETED ·Phase: PHASE3